20 completed, 10 recruiting, 5 unknown, 3 not yet recruiting. 14 Phase 2, 7 Not applicable, 5 Phase 1, 3 Phase 3, 2 Early Phase 1.
Follow Graves' Disease: new trials by email Literature Review of Graves' Disease trials Research Report on Graves' Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD) REGN24493, Placebo - Graves' Disease | Phase 1 | Not yet recruiting | Regeneron Pharmaceuticals | 45 | 2026-11-02 | 2026-10-06 |
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' Disease Study-related ophthalmological assessment and biospecimen collection, Blood biomarkers and standardized blood samples including thyroid function status - Graves' Orbitopathy, Thyroid Eye Disease, TED | Recruiting | University of Copenhagen | 430 | 2026-10-16 | 2026-10-27 | |
| A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old Felzartamab, Placebo - Graves' Disease | Phase 2 | Recruiting | Biogen | 60 | 2026-07-30 | 2026-10-22 |
| Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease ETHY-001, Placebo - Thyroid Eye Disease (TED), Graves' Disease | Phase 1 | Recruiting | Ethyreal Bio, Inc. | 72 | 2026-07-06 | 2026-10-26 |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Efgartigimod PH20 SC, Placebo PH20 SC - Graves' Disease, Graves Disease | Phase 3 | Recruiting | argenx | 230 | 2026-06-10 | 2026-10-16 |
| Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease Experimental: YB-101, Placebo YB-101 - Graves' Disease | Phase 2 | Recruiting | Yarrow Bioscience, Inc. | 232 | 2026-06-10 | 2026-10-05 |
| In Vivo CAR-T for Refractory Graves' Disease In Vivo CAR-T Therapy - Graves' Disease | Early Phase 1 | Recruiting | Shanghai Zhongshan Hospital | 5 | 2026-01-29 | 2026-03-19 |
| A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) IMVT-1402 - Graves' Disease | Phase 2 | Enrolling by invitation | Immunovant Sciences GmbH | 372 | 2026-01-26 | 2026-09-29 |
| Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease allogenic anti-CD19/BCMA CAR-T - Graves' Disease | Early Phase 1 | Recruiting | Shanghai Zhongshan Hospital | 4 | 2025-12-19 | 2026-01-05 |
| A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease Rilzabrutinib dose 1, Rilzabrutinib dose 2 - Graves' Disease | Phase 2 | Recruiting | Sanofi | 30 | 2025-09-02 | 2026-10-01 |
| Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease Ergocalciferol 50,000 IU, Methimazole - Graves Disease, Graves' Disease | Phase 2 | Active not recruiting | Northwell Health | 30 | 2025-08-25 | 2026-10-23 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 210 | 2025-06-19 | 2026-08-25 |
| Microbiota and Immune SignatureS of Graves' Disease and Orbitopathy Aspiration 0 - Graves' Orbitopathy, Graves' Disease | Not applicable | Active not recruiting | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 67 | 2025-02-25 | 2026-10-13 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 240 | 2024-12-17 | 2026-08-25 |
| Assessment of Thyroid Doppler Ultrasound in Followup of Pediatric Graves' Disease Graves' Disease | Not yet recruiting | Assiut University | 32 | 2024-08-05 | 2024-07-16 | |
| Graves' Disease Remission Study: MycoMeth Combo Mycophenolate Mofetil, Oral, 250 Mg, methimazole, oral, 10mg - Graves' Disease | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Xiamen University | 205 | 2023-10-16 | 2024-02-28 |
| Change of Gut Microbiome in the Treatment of Graves' Disease Antithyroid Drug - Graves' Disease | Completed | Seoul St. Mary's Hospital | 29 | 2020-05-19 | 2022-08-12 | |
| K1-70 - A Study in Subjects With Graves' Disease K1-70 intramuscular or K1-70 intravenous - Graves' Disease | Phase 1 | Completed | AV7 Limited | 18 | 2016-08-01 | 2021-05-20 |
| A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease CFZ533 - Graves' Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 15 | 2016-04-19 | 2021-01-05 |
Showing 20 of 41. Sign in to see all of them.
Graves Disease (41) · Hyperthyroidism (11) · Graves Ophthalmopathy (7) · Thyroid Diseases (4) · Endocrine System Diseases (2) · Eye Diseases (2) · Hypothyroidism (2) · Autoimmune Diseases (1) · Disease (1) · Disease Susceptibility (1) · Exophthalmos (1) · Eye Diseases, Hereditary (1) · Goiter (1) · Goiter, Nodular (1) · Hashimoto Disease (1)
Autoimmune Diseases (40) · Exophthalmos (40) · Goiter (40) · Immune System Diseases (40) · Orbital Diseases (40) · Endocrine System Diseases (39) · Eye Diseases (39) · Thyroid Diseases (37) · Hyperthyroidism (30) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Eye Diseases, Hereditary (6) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3)
Methimazole (5) · Antithyroid Agents (1) · Atorvastatin (1) · Blood Specimen Collection (1) · Bupivacaine (1) · Cholecalciferol (1) · Decision Support Techniques (1) · Dexamethasone (1) · Ergocalciferols (1) · Hematologic Tests (1) · Iodine-131 (1) · Lipids (1) · Methylprednisolone (1) · Mycophenolic Acid (1) · Radiotherapy (1)
Immunovant Sciences GmbH (3) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (2) · Mayo Clinic (2) · National Taiwan University Hospital (2) · Shanghai Zhongshan Hospital (2) · Xiao-Ming Mao (2) · AV7 Limited (1) · Assiut University (1) · Biogen (1) · Boston Children's Hospital (1) · Ethyreal Bio, Inc. (1) · Mashhad University of Medical Sciences (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Newcastle-upon-Tyne Hospitals NHS Trust (1) · Northwell Health (1)
United States (16) · Italy (6) · United Kingdom (6) · China (4) · Denmark (4) · Georgia (4) · Australia (3) · Germany (3) · Hungary (3) · Poland (3) · South Korea (3) · Spain (3) · Brazil (2) · Bulgaria (2) · Chile (2)
Birte Nygaard, M.D., Ph.D. (1) · Claudio Marcocci, MD (1) · Colum A. Gorman (1) · Dave Singh, Professor (1) · Dong-Jun Lim, MD, PhD (1) · Fangsen Xiao, MD (1) · Floriana Bytyqi, M.D (1) · Jens Pedersen, M.D., Ph.D. (1) · Joseph E Benabou (1) · Lars Rejnmark, Professor (1) · Laura S Ward, MD, PhD (1) · Mario Salvi, MD (1) · Marius Stan, MD (1)
PMID 19850691, PMID 11535445, PMID 16864757, PMID 18299459, PMID 21175612, PMID 21915479, PMID 22219499, PMID 26413979, PMID 26670972, PMID 27272078, PMID 27521067, PMID 27797318, PMID 29396246, PMID 30912336, PMID 31280470, PMID 31384956, PMID 31512728, PMID 31910101, PMID 32055040, PMID 32616746, PMID 32929476, PMID 34149627, PMID 34598995, PMID 35018442, PMID 35223896, PMID 35959915, PMID 36346684, PMID 37218433, PMID 39264438
2025 (3), 2015 (1), 2023 (1), R01DK042822 (1)